An Unexpected Effect of Maraviroc Could Make It a Future Treatment for Sarcoidosis

J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):83-84. doi: 10.18176/jiaci.0537. Epub 2020 Jun 23.

Authors

F Goehringer¹, A Tiotiu², E Schvoerer³, R Jaussaud⁴, B Hoen¹

Affiliations

¹ Infectious Diseases Department, Nancy University Hospital, Nancy, France.
² Pulmonology Department, Nancy University Hospital, Nancy, France.
³ Laboratory of Virology, Nancy University Hospital, Nancy, France.
⁴ Internal Medicine and Clinical Immunology Department, Nancy University Hospital, Nancy, France.

PMID: 32573460
DOI: 10.18176/jiaci.0537

No abstract available

Keywords: CD4+ lymphocytopenia; HIV infection; Maraviroc; Sarcoidosis; TH1 inflammation.

Publication types

Case Reports

MeSH terms

Adult
CCR5 Receptor Antagonists / therapeutic use*
CD4-Positive T-Lymphocytes / drug effects
CD4-Positive T-Lymphocytes / immunology*
HIV Infections / drug therapy*
HIV-1 / physiology*
Humans
Male
Maraviroc / therapeutic use*
Sarcoidosis / drug therapy*
Treatment Outcome

Substances

CCR5 Receptor Antagonists
Maraviroc